Literature DB >> 11862233

Phase II Trial of Paclitaxel in Patients with Advanced Colon Cancer Previously Untreated with Cytotoxic Chemotherapy: An Eastern Cooperative Oncology Group Trial (PA286).

Avi I. Einzig1, Donna Neuberg, Peter H. Wiernik, Louise B. Grochow, Guillermo Ramirez, Peter J. O'Dwyer, Nicholas J. Petrelli.   

Abstract

Paclitaxel was administered as a 24-h continuous infusion at 250 mg/m(2) in this Phase II trial in patients with adenocarcinoma of the colon or rectum. Nineteen patients were evaluated for toxity and 15 were assessable for response. There were no complete or partial responses, and toxicity present was primarily neutropenia. This study found that paclitaxel as a single agent does not have activity in adenocarcinoma of the colon or rectum.

Entities:  

Year:  1996        PMID： 11862233     DOI： 10.1097/00045391-199611000-00003

Source DB:  PubMed          Journal:  Am J Ther        ISSN： 1075-2765            Impact factor:   2.688


  7 in total

1.  Connexin 43 enhances paclitaxel cytotoxicity in colorectal cancer cell lines.

Authors:  Siqi Wang; Shiwu Zhang; Zhenying Zhao; Chunze Zhang; Xiaoyun Yang; Yijia Wang
Journal:  Exp Ther Med       Date:  2017-06-13       Impact factor: 2.447

2.  Rationally designed treatment for solid tumors with MAPK pathway activation: a phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach.

Authors:  Janice M Mehnert; Antoinette R Tan; Rebecca Moss; Elizabeth Poplin; Mark N Stein; Mika Sovak; Kelly Levinson; Hongxia Lin; Michael Kane; Murugesan Gounder; Yong Lin; Weichung Joe Shih; Eileen White; Eric H Rubin; Vassiliki Karantza
Journal:  Mol Cancer Ther       Date:  2011-06-16       Impact factor: 6.261

Review 3.  Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer.

Authors:  Shigenobu Emoto; Eiji Sunami; Hironori Yamaguchi; Soichiro Ishihara; Joji Kitayama; Toshiaki Watanabe
Journal:  Surg Today       Date:  2014-02-01       Impact factor: 2.549

4.  Impact of BMI1 expression on the apoptotic effect of paclitaxel in colorectal cancer.

Authors:  Hsiang-Lin Tsai; Shin-Yu Pang; Hui-Ching Wang; Chi-Wen Luo; Qiao-Lin Li; Tzu-Yi Chen; Shao-Yu Fang; Jaw-Yuan Wang; Mei-Ren Pan
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

5.  Targeting Colorectal Cancer Cells with Niosomes Systems Loaded with Two Anticancer Drugs Models; Comparative In Vitro and Anticancer Studies.

Authors:  Shaymaa Wagdy El-Far; Hadel A Abo El-Enin; Ebtsam M Abdou; Ola Elsayed Nafea; Rehab Abdelmonem
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-30

6.  Styrene maleic acid-encapsulated paclitaxel micelles: antitumor activity and toxicity studies following oral administration in a murine orthotopic colon cancer model.

Authors:  Neha N Parayath; Hayley Nehoff; Samuel E Norton; Andrew J Highton; Sebastien Taurin; Roslyn A Kemp; Khaled Greish
Journal:  Int J Nanomedicine       Date:  2016-08-17

Review 7.  Stress granules in colorectal cancer: Current knowledge and potential therapeutic applications.

Authors:  Noémie Legrand; Dan A Dixon; Cyril Sobolewski
Journal:  World J Gastroenterol       Date:  2020-09-21       Impact factor: 5.742
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.